Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 4Phase 3 2Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 35Neoplasm Metastasis 32Myelodysplastic Syndromes 18Lung Neoplasms 16Colorectal Neoplasms 14Pancreatic Neoplasms 12Breast Neoplasms 12Multiple Myeloma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Carcinoma, Non-Small-Cell Lung 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Melanoma 9Glioblastoma 9Lymphoma, Follicular 8Carcinoma, Renal Cell 8Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell 7Astrocytoma 7Ovarian Neoplasms 6Glioma 6Burkitt Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Lymphoma, T-Cell 5Lymphoma, Mantle-Cell 5Leukemia, Biphenotypic, Acute 5Hematologic Neoplasms 5Stomach Neoplasms 4

Interventions

ruxolitinib 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematopoietic and Lymphatic System Neoplasm × Specimen Handling × Clear all
NCT07025538 2026-04-20

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

City of Hope Medical Center

Phase 1 Recruiting
42 enrolled

Hematopoietic and Lymphatic System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡